DUBLIN--(BUSINESS WIRE)--The "Bronchopulmonary Dysplasia (BPD) - Market Insights, Epidemiology and Market Forecast-2028" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Bronchopulmonary Dysplasia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of BPD from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Study Period: 2017-2028
Companies Mentioned
- Medipost
- Windtree Therapeutics
- Therabron Therapeutics
- Shire
- Takeda
Epidemiology
The Bronchopulmonary Dysplasia epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken
The disease epidemiology covered in the report is segmented by Preterm and Early Preterm cases, Total cases of Bronchopulmonary Dysplasia, and Severity-specific cases [Mild, Moderate and Severe] in the 7MM
According to this research, the total prevalent cases of Bronchopulmonary Dysplasia was 64,468 in 2017 in 7MM. Among 7MM, estimates show higher population of Bronchopulmonary Dysplasia (BPD) in the United States, reaching to 14,243 cases in 2028
Drug Chapters
This segment of the Bronchopulmonary Dysplasia report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases
Market Outlook
The Bronchopulmonary Dysplasia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight
Currently, the treatment of Bronchopulmonary Dysplasia is dependent on ventilation, oxygen supplementation and supportive interventions such as steroids, surfactants, bronchodilators, vitamin A, methylxanthines, diuretics, antibiotics etc. However, many therapies remain controversial due to unacceptable side effects and randomized controlled trial testing and long-term outcome follow-up analysis. The management of BPD and its related problems thus remains a major challenge. However, improved understanding of the complex pathogenesis of BPD has led to the development of novel pharmacologic interventions for its prevention and treatment.
As per estimates, the market size of Bronchopulmonary Dysplasia was found to be USD 307.69 million in 2017. This market is further expected to grow during the forecasted period of 2019-2028, owing to the launch of upcoming therapies. Detailed chapters of the promising upcoming therapies including PNEUMOSTEM (Medipost), AEROSURF (Windtree Therapeutics), CG100 (Therabron Therapeutics), and SHP607 (Shire/ Takeda) are also provided in the report.
Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions
Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Key Strengths
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
Assessment
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Benefits
- This report will help to develop Business Strategies by understanding the trends shaping and driving the Bronchopulmonary Dysplasia market
- Organize sales and marketing efforts by identifying the best opportunities for Bronchopulmonary Dysplasia market
- To understand the future market competition in the Bronchopulmonary Dysplasia market
Key Topics Covered
1. Key Insights
2. Bronchopulmonary Dysplasia (BPD): Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Bronchopulmonary Dysplasia (BPD) in 2017
2.2. Total Market Share (%) Distribution of Bronchopulmonary Dysplasia (BPD) in 2028
3. Bronchopulmonary Dysplasia (BPD): Disease Background and Overview
3.1. Introduction
3.2. Risk Factors
3.3. Signs and symptoms
3.4. Pathophysiology
3.5. Biomarkers of BPD
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Cases of Bronchopulmonary Dysplasia in 7MM
4.3. United States Epidemiology
4.3.1. Assumptions and Rationale
4.3.2. Preterm and Early Preterm Cases in the United States
4.3.3. Total cases of Bronchopulmonary Dysplasia in the US
4.3.4. Severity Specific Cases of Bronchopulmonary Dysplasia in the United States
4.4. EU5 Epidemiology
4.5. Germany Epidemiology
4.6. France Epidemiology
4.7. Italy Epidemiology
4.8. Spain Epidemiology
4.9. United Kingdom Epidemiology
4.10. Japan Epidemiology
5. Treatment and Management of BPD
5.1. Bronchopulmonary Dysplasia: Evidence-Based Pharmacologic Therapies
5.2. Management of Bronchopulmonary Dysplasia - US Preventive Services Task Force
5.3. Guidelines for use of postnatal corticosteroids in preterm neonates have been endorsed by pediatric associations in North America and Europe
6. Unmet Needs
7. Emerging Therapies
7.1. Key Cross Competition
7.2. PNEUMOSTEM: Medipost
7.2.1. Product Description
7.2.2. Other Developmental Activities
7.2.3. Clinical Development
7.2.4. Safety and Efficacy
7.2.5. Product Profile
7.3. AEROSURF: Windtree Therapeutics
7.4. CG100: Therabron Therapeutics
7.5. SHP607: Shire/Takeda
8. Bronchopulmonary Dysplasia (BPD): 7MM Market Analysis
8.1. Key Findings
8.2. Market Size of Bronchopulmonary Dysplasia in 7MM
8.3. Market Size of Bronchopulmonary Dysplasia by Therapies in 7MM
8.4. United States: Market Outlook
8.4.1. United States Market Size
8.4.2. Total Market size of Bronchopulmonary Dysplasia
8.4.3. Market Size of Bronchopulmonary Dysplasia by Therapies in the US
8.5. EU-5 countries: Market Outlook
8.6. Germany Market Size
8.7. France Market Size
8.8. Italy Market Size
8.9. Spain Market Size
8.10. United Kingdom Market Size
8.11. Japan Market Outlook
9. Market Drivers
10. Market Barriers
11. Appendix
11.1. Report Methodology
12. Publisher Capabilities
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/lwxp9q
